At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 877 enrolled
Drug / intervention
Escitalopram +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Fixed-dose Study of Escitalopram in Adult Patients With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating Escitalopram and Placebo for Major Depressive Disorder. Completed, enrolled 877 participants across 45 sites.
Detailed Summary
This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the study may be eligible to enter a long-term open-label extension study with escitalopram.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedApr 29, 2008
Enrollment StartApr 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.2 years ago
Interventions
Escitalopramdrug
Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
Placebodrug
Placebo, oral administration, once daily dosing for 8 weeks
Escitalopramdrug
Escitalopram high dose, oral administration, once daily dosing for 8 weeks